Who It’s For

Who it’s for

From your first indication to your last denial.

Medical affairs, market access, sometimes the founder. See how Savvyn shows up at each stage of the evidence lifecycle — or explore what it does for your specific role.

Medical Affairs

Know what your evidence already proves, and where the real gaps are, before the payer asks.

Market Access

Walk into every submission knowing exactly what’s been required before, and how you measure up.

Early Founding Teams

Scope your first indication with the same evidence discipline as teams five years ahead of you.

Four stages, and the same underlying question at each one: what counts as enough evidence, and are you there yet?

Indication Scan · 3 candidates

Candidate use	Precedent	Payer path	Fit
NSCLC recurrence monitoring	4 cleared comparators	MolDx template exists	Strong
Pancreatic early detection	1 comparator, contested	No local coverage policy	Moderate
MRD in early-stage breast	No direct comparator	Precedent unclear	Unproven

Illustrative — anonymized example

01 · Before the studies

Which intended use should we go after?

Savvyn surfaces the precedent record for every candidate use — what’s already been cleared, covered, or contested — so you scope your first study against evidence, not guesswork.

Readiness vs. Comparator · approved comparator assay

Domain	Comparator had	You have	Status
Analytical validity	3 studies	3 studies	Met
Clinical validity	2 cohorts, n>500	1 cohort, n=180	Partial
Clinical utility	1 prospective RCT	None yet	Gap

Illustrative — anonymized example

02 · Building the evidence

How far are we from what’s already been approved?

Savvyn matches your evidence against the nearest approved comparator, domain by domain, so you know exactly what’s already met and what’s still a gap.

Cohort Prioritization · ranked

1 Stage III NSCLC, post-resectionStrongest precedent, fastest MolDx path Strongest evidence

2 Stage II colorectal, adjuvantGood precedent, 2 competing tests already covered Consider

3 Early-stage pancreaticHighest need, thinnest evidence base Longer runway

Illustrative — anonymized example

03 · Submissions running

Which cohort do we spend the money on?

Savvyn ranks your candidate cohorts by evidence strength and path to coverage, with the reasoning and data behind every position exposed.

Commercial payer denial — NSCLC recurrence monitoring: insufficient evidence of clinical utility.

Prospective cohort, 412 pts — utility endpoint met Strong

Retrospective validation, single site Moderate

Case series, n=18 — endpoint unclear Uncertain

04 · In market, no policy

Every denial has an answer already in your evidence.

Savvyn structures your evidence on one side, what’s already been required on the other, and matches them — graded, cited, and ready to use in the appeal.

Schedule a Call

From your first indication to your last denial.

Which intended use should we go after?

How far are we from what’s already been approved?

Which cohort do we spend the money on?

Every denial has an answer already in your evidence.

You don’t get paid for innovating. You get paid for proving it works.